Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Dan Leonard
RBC
Dan Leonard
Wall Street Analyst
★★☆☆☆
#1910
on 13Foresight · ranked by our own returns
56%
Success Rate
-0.1%
Average Return
23 of 41 calls profitable · -10.2% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 56% of Dan Leonard's ratings turned a profit when each position was held for 1 year — averaging -0.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

40 Buy 30 Hold 1 Sell
Dan's Stock Coverage 41 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
GH
Guardant Health
Jun 12, 2026 BUY Strong Buy
-5.8% avg upside
30 analysts
$185.00
40.37% Upside
-1.9%
NTRA
Natera
Jun 11, 2026 BUY Strong Buy
+7.6% avg upside
26 analysts
$275.00
18.86% Upside
+3.3%
A
Agilent
May 26, 2026 BUY Strong Buy
+3.9% avg upside
32 analysts
$153.00
20.32% Upside
+15.3%
TECH
Bio-Techne
May 14, 2026 BUY Strong Buy
+38.6% avg upside
21 analysts
$62.00
6.93% Upside
+25.5%
RGEN
Repligen
May 14, 2026 BUY Strong Buy
+28.3% avg upside
25 analysts
$160.00
21.22% Upside
+18.3%
ILMN
Illumina
May 14, 2026 BUY Buy
-10.0% avg upside
30 analysts
$170.00
4.96% Upside
+11.1%
BIO
Bio-Rad Laboratories
May 14, 2026 BUY Buy
+23.7% avg upside
8 analysts
$320.00
13.29% Upside
+15.6%
DHR
Danaher
May 14, 2026 BUY Strong Buy
+21.8% avg upside
45 analysts
$200.00
12.92% Upside
+10.2%
AVTR
Avantor
May 14, 2026 HOLD Buy
+49.6% avg upside
26 analysts
$9.00
6.14% Downside
+21.3%
TMO
Thermo Fisher
May 14, 2026 HOLD Strong Buy
+26.9% avg upside
38 analysts
$490.00
5.56% Upside
+5.5%
BRKR
Bruker
May 07, 2026 HOLD Buy
-7.0% avg upside
22 analysts
$45.00
21.39% Downside
+25.1%
CERT
Certara
Mar 09, 2026 BUY Buy
+133.3% avg upside
21 analysts
$10.00
80.57% Upside
-14.1%
CRL
Charles River Labs
Feb 25, 2026 HOLD Strong Buy
+12.0% avg upside
34 analysts
$175.00
5.49% Downside
+11.9%
TXG
10x Genomics
Feb 19, 2026 HOLD Buy
-26.8% avg upside
18 analysts
$20.00
42.47% Downside
+65.5%
WST
West Pharmaceutical Services
Feb 13, 2026 BUY Strong Buy
+6.5% avg upside
17 analysts
$340.00
3.63% Upside
+31.6%
WAT
Waters
Feb 10, 2026 HOLD Strong Buy
+3.5% avg upside
30 analysts
$370.00
4.19% Upside
+9.4%
QGEN
Qiagen
Feb 09, 2026 HOLD Buy
+14.1% avg upside
23 analysts
$52.00
40.71% Upside
-35.5%
IQV
IQVIA Holdings
Feb 06, 2026 BUY Strong Buy
+34.3% avg upside
38 analysts
$240.00
43.12% Upside
-4.9%
CYRX
CryoPort
Nov 05, 2025 BUY Strong Buy
-3.8% avg upside
15 analysts
$12.50
16.74% Downside
+54.0%
ICLR
Icon
Oct 24, 2025 BUY Strong Buy
+24.0% avg upside
25 analysts
$220.00
50.60% Upside
-17.1%
STVN
Stevanato Group
Aug 06, 2025 HOLD Strong Buy
+54.2% avg upside
13 analysts
$28.00
59.64% Upside
-85.1%
MEDP
Medpace Holdings
Jul 29, 2025 SELL Buy
-12.0% avg upside
16 analysts
$305.00
33.71% Downside
-4.3%
MTD
Mettler-Toledo
May 19, 2025 BUY Buy
+2.7% avg upside
18 analysts
$1350.00
17.83% Upside
-9.3%
RVTY
Revvity
May 01, 2025 BUY Buy
+5.5% avg upside
23 analysts
$115.00
15.09% Upside
-6.4%
FLGT
Fulgent Genetics
Mar 02, 2025 HOLD Buy
+143.4% avg upside
7 analysts
$20.00
11.10% Upside
-7.1%
MRVI
Maravai Lifesciences Holdings
Aug 08, 2024 HOLD Strong Buy
+175.0% avg upside
17 analysts
$11.00
111.52% Upside
-74.1%
GB:0AI4
Carlsberg AS
Apr 08, 2024 HOLD Buy
+20.7% avg upside
20 analysts
$960.00
15.87% Upside
·
ADPT
Adaptive Biotechnologies
Feb 14, 2023 SELL Strong Buy
+20.0% avg upside
14 analysts
$7.00
59.98% Downside
+54.6%
LH
Labcorp Holdings
Feb 11, 2022 BUY Strong Buy
+1.8% avg upside
36 analysts
$320.00
25.06% Upside
-10.2%
DGX
Quest Diagnostics
Feb 04, 2022 HOLD Buy
-12.4% avg upside
33 analysts
$145.00
25.64% Downside
+8.6%
RHP
Ryman
Oct 18, 2021 BUY Strong Buy
-5.9% avg upside
18 analysts
$95.00
24.08% Downside
-0.6%
BIORQ
Biora Therapeutics
Jul 14, 2020 BUY Strong Buy
+269249900.0% avg upside
6 analysts
$11.00
10999899.92% Upside
·
MYGN
Myriad Genetics
Aug 14, 2019 HOLD Hold
+315.3% avg upside
24 analysts
$35.00
670.96% Upside
-50.3%
BDX
Becton Dickinson
Dec 06, 2018 BUY Buy
+35.6% avg upside
25 analysts
$280.00
94.39% Upside
+9.4%
TTOO
T2 Biosystems
Jul 08, 2016 BUY Buy
+1473337.5% avg upside
10 analysts
$7.00
1399900.07% Upside
·
CDNA
CareDx
Jun 20, 2016 BUY Buy
+26.1% avg upside
16 analysts
-78.8%
VCYT
Veracyte
Jun 20, 2016 BUY Strong Buy
-19.0% avg upside
17 analysts
+48.7%
ABT
Abbott Laboratories
Jun 16, 2016 HOLD Strong Buy
+31.2% avg upside
35 analysts
+31.8%
HTGMQ
HTG Molecular Diagnostics
May 23, 2016 BUY Buy
+7333233.3% avg upside
6 analysts
$4.00
3999899.99% Upside
·
CRDF
Cardiff Oncology
May 11, 2016 HOLD Strong Buy
+736.8% avg upside
18 analysts
$3.50
189.19% Upside
-79.0%
LAB
Standard BioTools
Apr 12, 2016 BUY Strong Buy
+645.1% avg upside
8 analysts
$15.00
1707.95% Upside
-43.7%
🔒 36 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Dan Leonard — Frequently Asked Questions
How accurate are Dan Leonard's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Dan's ratings were profitable over a one-year hold, with an average return of -0.1% per rating, or -9.7% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Dan ranked on 13Foresight?
Dan Leonard is currently ranked #1910 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Dan cover?
Dan most recently has ratings on GH, NTRA, A, TECH, RGEN, ILMN, BIO, DHR, AVTR, TMO, BRKR, CERT and 29 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.